ADMA Biologics Inc (OQ:ADMA)

Mar 11, 2024 07:00 am ET
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the United States Food and Drug...
Mar 05, 2024 07:00 am ET
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief...
Feb 28, 2024 04:10 pm ET
ADMA Biologics Announces CFO Transition
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that Brian Lenz, Executive Vice President,...
Feb 28, 2024 04:05 pm ET
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its fourth quarter and full year 2023...
Feb 21, 2024 04:05 pm ET
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full...
Feb 21, 2024 07:00 am ET
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced the successful initial use of its...
Jan 08, 2024 07:00 am ET
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its preliminary unaudited fourth quarter and...
Dec 18, 2023 04:05 pm ET
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced the Company has executed a...
Dec 12, 2023 07:00 am ET
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced the U.S. Food and Drug...
Nov 16, 2023 07:00 am ET
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S....
Nov 08, 2023 04:05 pm ET
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its third quarter 2023...
Nov 01, 2023 07:00 am ET
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report third...
Aug 09, 2023 04:05 pm ET
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its second quarter 2023...
Aug 02, 2023 07:00 am ET
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report second...
Jul 19, 2023 07:00 am ET
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S....
May 10, 2023 04:05 pm ET
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its first quarter 2023...
May 03, 2023 07:00 am ET
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report first...
May 02, 2023 07:00 am ET
ADMA Biologics Announces Amendment to Credit Agreement
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced the Company has amended the...
Mar 23, 2023 04:05 pm ET
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its fourth quarter and full...
Mar 16, 2023 07:00 am ET
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report fourth...
Feb 08, 2023 07:00 am ET
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S....
Jan 17, 2023 07:00 am ET
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported that it expects preliminary,...
Dec 13, 2022 07:00 am ET
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the United States Food and...
Dec 09, 2022 04:05 pm ET
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously...
Dec 07, 2022 08:45 am ET
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced...
Dec 06, 2022 04:05 pm ET
ADMA Biologics Announces Proposed Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer...
Dec 06, 2022 04:01 pm ET
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced preliminary estimates for its...
Nov 09, 2022 04:05 pm ET
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its third quarter 2022...
Nov 02, 2022 07:00 am ET
ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial...
Oct 31, 2022 07:00 am ET
ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug...
Aug 10, 2022 04:05 pm ET
ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its second quarter 2022...
Aug 03, 2022 07:00 am ET
ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial...
Jun 21, 2022 07:00 am ET
ADMA Biologics Announces Addition to the Russell 2000® Index
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Company will be...
May 11, 2022 04:05 pm ET
ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its first quarter 2022...
May 04, 2022 07:00 am ET
ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial...
Apr 01, 2022 07:00 am ET
ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced a poster presentation and...
Mar 25, 2022 07:00 am ET
ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the United States Food and Drug Administration’s...
Mar 24, 2022 04:05 pm ET
ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its fourth quarter and full...
Mar 21, 2022 07:00 am ET
ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial...
Mar 07, 2022 04:05 pm ET
ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug...
Jan 19, 2022 07:35 am ET
Thinking about buying stock in Zogenix, KE Holdings, SoFi Technologies, Leap Therapeutics, or ADMA Biologics?
NEW YORK, Jan. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZGNX, BEKE, SOFI, LPTX, and ADMA.
Jan 19, 2022 07:00 am ET
ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its preliminary unaudited...
Jan 18, 2022 07:00 am ET
ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug...
Dec 21, 2021 07:00 am ET
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan
ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption...
Dec 09, 2021 07:00 am ET
ADMA Biologics Provides Update on Global Intellectual Property Portfolio
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the European Patent...
Nov 17, 2021 07:00 am ET
ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Cyndi Tolman, ADMA’s...
Nov 16, 2021 07:00 am ET
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and...
Nov 11, 2021 08:31 am ET
Thinking about buying stock in Sally Beauty, DiDi Global, Fossil Group, ADMA Biologics, or Root Inc?
NEW YORK, Nov. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SBH, DIDI, FOSL, ADMA, and ROOT.
Nov 10, 2021 04:01 pm ET
ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the...
Nov 03, 2021 07:00 am ET
ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial...
Oct 25, 2021 04:01 pm ET
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten...
Oct 22, 2021 07:00 am ET
ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that a poster presentation...
Oct 21, 2021 09:00 am ET
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced...
Oct 20, 2021 04:01 pm ET
ADMA Biologics Announces Proposed Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer...
Oct 19, 2021 07:00 am ET
ADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that a poster presentation...
Oct 18, 2021 07:00 am ET
ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T....
Oct 04, 2021 07:00 am ET
ADMA Biologics Announces the Presentation of Real-World Experience in the Management of Respiratory Syncytial Virus (RSV) Presented at IDWeek 2021
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced on-demand access to an...
Oct 01, 2021 07:00 am ET
ADMA Biologics Announces Presentation on Respiratory Viral Infections at IDWeek 2021
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an exclusive educational...
Sep 23, 2021 07:00 am ET
ADMA Biologics to Virtually Participate in the Cantor Healthcare Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief...
Sep 08, 2021 08:30 am ET
Thinking about buying stock in Kadmon Holdings, ADMA Biologics, National CineMedia, Coupa Software, or Gain Therapeutics?
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KDMN, ADMA, NCMI, COUP, and GANX.
Sep 08, 2021 07:00 am ET
ADMA Biologics Receives FDA Approval for VanRx Aseptic Fill-Finish Machine and Related Operations
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that the U.S. Food and Drug...
Sep 02, 2021 07:00 am ET
ADMA Biologics to Virtually Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief...
Aug 16, 2021 08:30 am ET
Thinking about buying stock in Travere Therapeutics, ADMA Biologics, Surgalign, CTI BioPharma, or OpGen?
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TVTX, ADMA, SRGA, CTIC, and OPGN.
Aug 16, 2021 07:00 am ET
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug...
Aug 11, 2021 04:05 pm ET
ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the...
Aug 10, 2021 04:30 pm ET
ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and initiation of...
Aug 09, 2021 07:00 am ET
ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB®
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commercial availability of additional vial sizes...
Aug 04, 2021 07:00 am ET
ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial...
Jul 20, 2021 07:00 am ET
ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the United States Food and Drug Administration...
Jun 14, 2021 07:00 am ET
ADMA Biologics to Participate in the Raymond James Human Health Innovation Virtual Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief...
May 26, 2021 07:00 am ET
ADMA Biologics to Participate in the Jefferies Virtual Healthcare Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief...
May 12, 2021 04:05 pm ET
ADMA Biologics Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress and Accomplishments
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for its...
May 05, 2021 07:00 am ET
ADMA Biologics to Report First Quarter 2021 Financial Results on May 12, 2021
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the...
Apr 28, 2021 07:00 am ET
ADMA Biologics Receives FDA Approval for Increased IVIG Production Scale
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that the U.S. Food and Drug...
Apr 26, 2021 08:00 am ET
ADMA Biologics Opens Newest ADMA BioCenters Plasma Collection Facility in Goose Creek, S.C.
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced commencement of operations and initiation of donor...
Apr 13, 2021 08:00 am ET
ADMA Biologics Announces Poster Presentation Highlighting Pharmacoeconomic Burden of HIV and HBV Infection in Sexual Assault Patients at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meetin
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced a poster presentation at the...
Mar 25, 2021 04:05 pm ET
ADMA Biologics Reports Fourth Quarter and Full Year 2020 Financial Results
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for its...
Mar 18, 2021 08:00 am ET
ADMA Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the...
Mar 04, 2021 08:00 am ET
ADMA Biologics to Participate in the Jefferies Virtual Plasma Summit
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President...
Mar 03, 2021 08:00 am ET
ADMA Biologics Expands Global Regulatory Approval Presence and Announces FDA Approval to Commence Hepatitis B Plasma Collections
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its plasma collection center located in...
Feb 26, 2021 08:00 am ET
ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annua
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the presentation of a...
Feb 22, 2021 08:00 am ET
ADMA Biologics to Participate in Raymond James Institutional Investor Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President...
Feb 01, 2021 08:00 am ET
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Knoxville, TN
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug...
Jan 26, 2021 08:00 am ET
ADMA Biologics Receives Unique Permanent J-Code for ASCENIV™
ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Centers for Medicare and Medicaid Services...
Jan 19, 2021 08:00 am ET
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its preliminary unaudited...
Jan 04, 2021 08:00 am ET
ADMA Biologics Receives Unique Temporary C-Code and Pass-Through Payment Status for ASCENIV™
ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Centers for Medicare and Medicaid Services...
Dec 16, 2020 04:15 pm ET
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan
ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption...
Dec 09, 2020 08:00 am ET
ADMA Biologics Enters Into $100 Million Credit Facility Loan Amendment with Perceptive Advisors
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an amendment to its existing...
Dec 01, 2020 07:00 am ET
ADMA Biologics Opens Newest ADMA BioCenters Plasma Collection Facility in Maryville, TN
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced commencement of operations and initiation of...
Nov 10, 2020 07:00 am ET
ADMA Biologics to Participate in Jefferies 2020 Virtual London Healthcare Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President...
Nov 05, 2020 04:05 pm ET
ADMA Biologics Reports Third Quarter 2020 Financial Results and Business Highlights
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for its...
Oct 29, 2020 07:00 am ET
ADMA Biologics to Report Third Quarter 2020 Financial Results and Business Highlights on November 5, 2020
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the Company will host a live conference call...
Oct 21, 2020 07:00 am ET
ADMA Biologics Announces Presentation on Respiratory Viral Infections and New Data on S. Pneumoniae at IDWeek 2020
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced an exclusive educational...
Sep 09, 2020 07:00 am ET
ADMA Biologics to Participate in Morgan Stanley Virtual Healthcare Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President...
Sep 03, 2020 07:00 am ET
ADMA Biologics Highlights Launch of COVID-19 ImmunoRank™ Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the launch of COVID-19 ImmunoRank...
Sep 02, 2020 07:00 am ET
ADMA Biologics to Participate in Upcoming Investor Conferences
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President...
Aug 05, 2020 04:05 pm ET
ADMA Biologics Reports Business Highlights and Second Quarter 2020 Financial Results
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported business highlights and financial results for...
Jul 30, 2020 09:31 am ET
Thinking about buying stock in ADMA Biologics, Pacific Ethanol, Crocs Inc, Arlo Technologies, or Southwest Airlines?
NEW YORK, July 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADMA, PEIX, CROX, ARLO, and LUV.
Jul 29, 2020 07:00 am ET
ADMA Biologics to Report Business Highlights and Second Quarter 2020 Financial Results on August 5, 2020
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the Company will host a live conference call...
Jul 06, 2020 07:00 am ET
ADMA Biologics Opens Its Newest ADMA BioCenters Plasma Collection Facility
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the commencement of operations and initiation...
Jun 23, 2020 07:00 am ET
ADMA Biologics Announces Martha J. Demski Elected to Board of Directors
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the proposed resolution to elect Martha...
May 27, 2020 07:00 am ET
ADMA Biologics to Participate in Jefferies Virtual Healthcare Conference
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients...
May 21, 2020 07:00 am ET
ADMA Biologics Commences Collection of COVID-19 Plasma from Recovered Patients
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), today announced it has commenced the collection of convalescent plasma through its wholly-owned subsidiary, ADMA BioCenters Georgia Inc. (“ADMA BioCenters”), from individuals who have recovered from...
May 07, 2020 08:42 am ET
CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration
OSAKA, Japan, and KING OF PRUSSIA, Pa., May 7, 2020 /PRNewswire/ -- The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building momentum. Its membership has expanded globally to include 10 plasma companies, and now also includes global organizations from outside the plasma industry who are providing vital support to encourage more people to donate plasma.
May 07, 2020 07:35 am ET
ADMA Biologics Provides Corporate Update on Supply Chain Robustness and Recent Accomplishments
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immuno-deficient patients at risk for...
May 06, 2020 04:05 pm ET
ADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Apr 29, 2020 07:00 am ET
ADMA Biologics to Report First Quarter 2020 Financial Results on May 6, 2020
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Mar 12, 2020 04:05 pm ET
ADMA Biologics Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Mar 05, 2020 06:59 am ET
ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Mar 03, 2020 07:00 am ET
ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections
ADMA Biologics (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at...
Feb 24, 2020 07:00 am ET
ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Feb 11, 2020 04:20 pm ET
ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™
ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and...
Feb 06, 2020 08:41 pm ET
ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients...
Feb 06, 2020 04:06 pm ET
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients...
Jan 09, 2020 07:00 am ET
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook
ADMA Biologics, Inc. (NASDAQ: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and...
Jan 07, 2020 07:00 am ET
ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions
ADMA Biologics, Inc. (NASDAQ: ADMA), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the...
Dec 17, 2019 07:08 am ET
ADMA Biologics Added to NASDAQ Biotechnology Index
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Nov 13, 2019 07:08 am ET
ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Nov 06, 2019 05:02 pm ET
ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
ADMA Biologics, Inc. (NASDAQ: ADMA) (ADMA or the Company), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Nov 04, 2019 07:08 am ET
ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Oct 22, 2019 07:48 am ET
ADMA Biologics Named Company of the Year by BioFlorida
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Oct 21, 2019 07:48 am ET
ADMA Biologics Announces First Commercial Sales of ASCENIV™
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Oct 17, 2019 07:29 am ET
ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for...
Oct 07, 2019 07:08 am ET
ADMA Biologics Announces Data Presented at IDWeek 2019
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Oct 03, 2019 07:08 am ET
ADMA Biologics Announces Poster Presentation at IDWeek 2019
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Sep 23, 2019 07:08 am ET
ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Aug 22, 2019 07:48 am ET
ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures and markets three approved plasma-derived biologics for the treatment of...
Aug 08, 2019 07:08 am ET
ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Jul 08, 2019 08:22 am ET
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
May 29, 2019 07:11 am ET
ADMA Biologics to Present at Upcoming Investor Conferences
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
May 21, 2019 04:20 pm ET
ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
May 17, 2019 07:11 am ET
ADMA Biologics Announces Pricing of Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
May 16, 2019 08:00 am ET
NeuBase Therapeutics Designates Industry Leaders to Board of Directors 
NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology industry for its...
May 15, 2019 04:35 pm ET
ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
May 10, 2019 06:58 am ET
FDA Approves Prior Approval Supplement for BIVIGAM®
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
May 08, 2019 04:18 pm ET
ADMA Biologics Reports First Quarter 2019 Financial Results
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
May 03, 2019 07:18 am ET
ADMA Biologics Elects to Draw-Down $27.5 Million in Capital from Existing Perceptive Advisors Credit Agreement
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Apr 17, 2019 07:50 am ET
Report: Exploring Fundamental Drivers Behind Franco-Nevada, ADMA Biologics, GSI Technology, CryoLife, Simpson Manufacturing, and Pioneer Power Solutions — New Horizons, Emerging Trends, and Upcoming D
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Franco-Nevada Corporation (NYSE:FNV), ADMA Biologics Inc (NASDAQ:ADMA),...
Apr 17, 2019 07:08 am ET
ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia...
Apr 02, 2019 06:58 pm ET
ADMA Receives Department of Health and Human Services U.S. License
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune...
Apr 01, 2019 08:09 pm ET
FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune...
Mar 13, 2019 05:05 pm ET
ADMA Biologics Reports Full Year 2018 Financial Results
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Feb 25, 2019 07:38 am ET
ADMA Biologics to Present at Upcoming Investor Conferences
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Jan 07, 2019 07:08 am ET
ADMA Biologics Submits Response and Provides Supplemental Information to FDA for BIVIGAM® Complete Response Letter
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Dec 20, 2018 06:08 am ET
ADMA to Host Conference Call to Discuss Recent Regulatory Update on BIVIGAM® PAS Submissions
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune...
Dec 19, 2018 05:58 pm ET
ADMA Biologics Provides Regulatory Update on BIVIGAM® PAS Submissions
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Dec 19, 2018 09:18 am ET
ADMA Biologics Provides Regulatory Update for BIVIGAM®
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), announces that as of the time of this press release the Company has not received any formal written communication from the U.S. Food and Drug Administration regarding BIVIGAM’s Prior...
Nov 13, 2018 08:10 am ET
Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Evelo Biosciences, Inc. (NASDAQ:EVLO), ADMA Biologics Inc (NASDAQ:ADMA),...
Nov 08, 2018 05:05 pm ET
ADMA Biologics Reports Third Quarter 2018 Financial Results
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency...
Oct 17, 2018 07:08 am ET
ADMA Biologics Receives PDUFA Date for RI-002
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency...
Oct 11, 2018 08:48 am ET
ADMA Biologics Provides Regulatory Update for BIVIGAM®
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of...
Oct 03, 2018 07:08 am ET
ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency...
Oct 01, 2018 07:08 am ET
ADMA Biologics Resubmits Biologics License Application for RI-002
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency...
Sep 05, 2018 07:08 am ET
ADMA Biologics Reports FDA Compliance Status for its Manufacturing Facility has Improved
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain...
Aug 27, 2018 07:28 am ET
ADMA Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
ADMA Biologics, Inc. (NASDAQ: ADMA) (the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease...
Aug 10, 2018 07:08 am ET
ADMA Biologics Reports Second Quarter 2018 Financial Results
ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”) today announced its financial results for the quarter ended June 30, 2018 and provided an update on its operations and corporate objectives. “During the quarter we strengthened our...
Jul 26, 2018 10:50 am ET
ADMA Biologics Reports Successful Close-Out of its April 2018 FDA Compliance Inspection
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain...
Jul 26, 2018 07:58 am ET
ADMA Biologics Receives PDUFA Date for BIVIGAM® Regulatory Submission
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain...
Jun 25, 2018 07:08 am ET
ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes
ADMA Biologics, Inc. (NASDAQ:ADMA), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain infectious diseases, today...
Jun 12, 2018 04:05 pm ET
ADMA Biologics Announces Closing of $40M Public Offering
ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”) announced today the closing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share.  The gross...
Jun 08, 2018 09:08 am ET
ADMA Biologics Announces Pricing of Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”) announced today the pricing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share, resulting in...
Jun 07, 2018 04:05 pm ET
ADMA Biologics Announces Proposed Public Offering of Common Stock
ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”) announced today that it has commenced an underwritten public offering of its common stock.  The Company intends to grant the underwriters of the offering a 30-day option to purchase up to...
May 16, 2018 07:30 am ET
ADMA Biologics Granted U.S. Patent for Treating Respiratory Infections
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”) today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 9,969,793 covering methods of treating respiratory infections. The newly issued...
May 14, 2018 05:05 pm ET
ADMA Biologics Reports First Quarter 2018 Financial Results
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), today announced its financial results for the quarter ended March 31, 2018 and provided an update on its operations and corporate objectives. “During the first quarter, we achieved...
May 14, 2018 01:17 pm ET
ADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest
ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”) announced today that it has negotiated the receipt and immediate retirement of approximately 8.6 million shares of its non-voting common stock previously issued to Biotest Pharmaceuticals...
Apr 24, 2018 07:28 am ET
ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership
Operational Leadership Team Executes on Production and Commercialization of the Company’s Immune Globulin Product for the Treatment of Hepatitis B Infection
Mar 05, 2018 07:00 am ET
ADMA Biologics Reports Full Year 2017 Financial Results
RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for...
Feb 27, 2018 07:08 am ET
ADMA Biologics to Present at Raymond James’ 39th Annual Institutional Investors Conference
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of...
Dec 11, 2017 07:08 am ET
ADMA Files Biologics License Application For Its Third Plasma Collection Center
ADMA BioCenters’ Newest Facility Commences Operations to Further Supplement Supply of Internally-Sourced Donor Plasma for Commercial Products and Pipeline of Hyperimmune IG Candidates
Nov 15, 2017 08:08 am ET
ADMA Biologics Further Enhances Intellectual Property Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Compositions
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) is a vertically integrated biopharmaceutical and specialty immunoglobulin company that develops, manufactures and commercializes plasma-based biologics for the treatment of immune deficiencies...
Nov 13, 2017 12:30 pm ET
ADMA Biologics Announces Closing of $42M Follow-On Offering
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets plasma-based biologics designed to...
Nov 09, 2017 08:58 am ET
ADMA Biologics Announces Pricing of Follow-On Offering
RAMSEY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics designed to treat Primary Immune...
Nov 03, 2017 05:02 pm ET
ADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
RAMSEY, N.J., Nov. 03, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary...
Aug 11, 2017 04:15 pm ET
ADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
RAMSEY, N.J., Aug. 11, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious diseases, today announced its financial results for the quarter ended June 30, 2017 and provided a corporate update....
Jul 31, 2017 04:15 pm ET
ADMA Biologics Strengthens Patent Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Methods
RAMSEY, N.J. and BOCA RATON, Fla., July 31, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) is a vertically integrated biopharmaceutical and specialty immunoglobulin  company  that develops, manufactures and commercializes specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, announced today that the United States Patent and Trademark Office has issued to the Company U.S. Patent No. 9,714,283, which encompasses methods of providing immunotherapy to patients using immune globulin compositions proprietary t...
May 25, 2017 04:15 pm ET
ADMA Biologics to Present at Jefferies 2017 Healthcare Conference
RAMSEY, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced that Adam Grossman, President and CEO is scheduled to provide a corporate overview at the Jefferies 2017 Healthcare Conference on June 8, 2017 at 8:30 AM ET....
Mar 27, 2017 06:39 pm ET
Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA
NEW YORK, March 27, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating  ADMA Biologics, Inc. ("ADMA" or the "Company")(NasdaqGS: ADMA)  and its Board of Directors for potential securities laws violations and/or breaches of fiduciary duties in connection with the Purchase Agreement with Biotest Pharmaceuticals Corporation for its therapy business (the "Purchase Agreement").  
Feb 24, 2017 04:37 pm ET
ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones
RAMSEY, N.J., Feb. 24, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2016....
Nov 10, 2016 04:30 pm ET
ADMA Biologics Reports Third Quarter 2016 Results
RAMSEY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the quarter ended September 30, 2016....
Sep 01, 2016 07:38 am ET
ADMA Biologics to Present at Upcoming Investor Conferences
RAMSEY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention and treatment of certain infectious diseases, announced today that Adam Grossman, President and CEO is scheduled to provide a corporate overview at the following two September investor conferences:...
Aug 12, 2016 04:38 pm ET
ADMA Biologics Reports Second Quarter 2016 Results
RAMSEY, N.J., Aug. 12, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the quarter ended June 30, 2016....
Aug 01, 2016 04:31 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ADMA Biologics, Inc. (ADMA)
NEW YORK, Aug. 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ADMA Biologics, Inc. ("ADMA" or the "Company") (Nasdaq: ADMA). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at [email protected] or 212-697-6484.
Aug 01, 2016 03:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, Aug. 1, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jul 29, 2016 07:14 pm ET
ADMA Biologics Receives Complete Response Letter from FDA for Pending Biologics License Application
RAMSEY, N.J., July 29, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s Biologics License Application (BLA) for RI-002, an Intravenous Immune Globulin (IVIG), for the treatment of patients with Primary Humoral Immunodeficiency Disease (PI...
Jun 16, 2016 07:38 am ET
ADMA Biologics to Present at the 2016 JMP Securities Life Sciences Conference
RAMSEY, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the 2016 JMP Securities Life Sciences Conference on June 21, 2016 at The St. Regis New York....
May 13, 2016 05:05 pm ET
ADMA Biologics Reports First Quarter 2016 Results
RAMSEY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the quarter ended March 31, 2016, and recent accomplishments and anticipated milestones for 2016....
May 13, 2016 04:05 pm ET
ADMA Biologics Further Enhances Cash Position by Securing $4.0 Million in Additional Capital Through Amended Loan and Security Agreement with Oxford Finance
RAMSEY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that it has accessed an additional $4.0 million from its lender, Oxford Finance LLC (Oxford), made available through an amendment of the parties' existing loan and security agreement.  The amendment provides ADMA with the option to draw an additional $5 million upon the approval for its Biologics Licen...
May 03, 2016 10:46 am ET
ADMA Biologics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
RAMSEY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 1,892,308 shares of its common stock at a public offering price of $6.50 per share, as well as 283,846 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.  ...
Apr 28, 2016 09:15 am ET
ADMA Biologics Announces Pricing of Public Offering of Common Stock
RAMSEY, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the pricing of its previously announced underwritten public offering of 1,892,308 shares of common stock at a public offering price of $6.50 per share, resulting in gross proceeds of approximately $12.3 million. Members of management and the Board of Directors participated in excess of ten percent i...
Apr 27, 2016 04:05 pm ET
ADMA Biologics Announces Proposed Public Offering of Common Stock
RAMSEY, N.J., April 27, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering.  The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any.  The proposed offering is subject to market and other condi...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.